FDG PET/CT in pancreatic and hepatobiliary carcinomas: Value to patient management and patient outcomes

PET Clinics

Volumn 10, Issue 3, 2015, Pages 327-343

  Parikh, Ujas ^a   Marcus, Charles ^a   Sarangi, Rutuparna ^a   Taghipour, Mehdi ^a   Subramaniam, Rathan M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

18F FDG PET CT; Hepatocellular carcinoma; Pancreatic cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; CANCER DIAGNOSIS; CANCER STAGING; COLORECTAL LIVER METASTASIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; GALLBLADDER CANCER; HEPATOBILIARY SYSTEM CANCER; HUMAN; LIVER CELL CARCINOMA; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CARCINOMA; PANCREATITIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; BILE DUCT TUMOR; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GALLBLADDER TUMOR; LIVER TUMOR; MALE; MULTIMODAL IMAGING; PANCREAS TUMOR; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING; TREATMENT OUTCOME;

BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; FEMALE; FLUORODEOXYGLUCOSE F18; GALLBLADDER NEOPLASMS; HUMANS; LIVER NEOPLASMS; MALE; MULTIMODAL IMAGING; NEOPLASM STAGING; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84931957361     PISSN: 15568598     EISSN: 18799809     Source Type: Journal    
DOI: 10.1016/j.cpet.2015.03.001     Document Type: Review

References (59)

1. American Cancer Society Cancer facts & figures 2014 2014 American Cancer Society Atlanta (GA)
2. P. Michl, S. Pauls, and T.M. Gress Evidence-based diagnosis and staging of pancreatic cancer Best Pract Res Clin Gastroenterol 20 2 2006 227 251
3. E.H. Dibble, D. Karantanis, and G. Mercier PET/CT of cancer patients: part 1, pancreatic neoplasms AJR Am J Roentgenol 199 5 2012 952 967
4. W. Marsh Rde, K.T. Hagler, and H.R. Carag Pancreatic panniculitis Eur J Surg Oncol 31 2005 1213 1215
5. G.J. Krejs Pancreatic cancer: epidemiology and risk factors Dig Dis 28 2 2010 355 358
6. National comprehensive cancer network website. NCCN guidelines version 1.2014: pancreatic adenocarcinoma. Available at: www.nccn.org/professionals/physician-gls/pdf/pancreatic.pdf. Accessed July 14, 2014.
7. T. Hennedige, and S.K. Venkatesh Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring Cancer Imaging 12 2013 530 547
8. A. Sacks, P.J. Peller, and D.S. Surasi Value of PET/CT in the management of liver metastases, part 1 AJR Am J Roentgenol 197 2011 W256 W259
9. A. Sacks, P.J. Peller, and D.S. Surasi Value of PET/CT in the management of primary hepatobiliary tumors, part 2 AJR Am J Roentgenol 197 2011 W260 W265
10. N. Ismaili Treatment of colorectal liver metastases World J Surg Oncol 9 2011 154
11. M.C. Bragazzi, V. Cardinale, and G. Carpino Cholangiocarcinoma: epidemiology and risk factors Transl Gastrointest Cancer 1 2012 21 32
12. J. Davison, G. Mercier, and G. Russo PET-based primary tumor volumetric parameters and survival of patients with non-small cell lung carcinoma AJR Am J Roentgenol 200 3 2013 635 640
13. A. Agarwal, A. Chirindel, and B.A. Shah Evolving role of FDG PET/CT in multiple myeloma imaging and management AJR Am J Roentgenol 200 4 2013 884 890
14. T. Jackson, M.K. Chung, and G. Mercier FDG PET/CT interobserver agreement in head and neck cancer: FDG and CT measurements of the primary tumor site Nucl Med Commun 33 3 2012 305 312
15. V. Paidpally, A. Chirindel, and S. Lam FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma Imaging Med 4 6 2012 633 647
16. D. Hadiprodjo, T. Ryan, and M.T. Truong Parotid gland tumors: preliminary data for the value of FDG PET/CT diagnostic parameters AJR Am J Roentgenol 198 2012 W185 W190
17. A.J. Antoniou, C. Marcus, and A.K. Tahari Follow-up or surveillance 18F-FDG PET/CT and survival outcome in lung cancer patients J Nucl Med 55 7 2014 1062 1068
18. D. Karantanis, D. Kalkanis, and J. Czernin Perceived misinterpretation rates in oncologic 18F-FDG PET/CT studies: a survey of referring physicians J Nucl Med 55 12 2014 1925 1929
19. P. Sridhar, G. Mercier, and J. Tan FDG PET metabolic tumor volume segmentation and pathologic volume of primary human solid tumors AJR Am J Roentgenol 202 5 2014 1114 1119
20. A.P. Rijkers, R. Valkema, and H.J. Duivenvoorden Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: a meta-analysis Eur J Surg Oncol 40 7 2014 794 804
21. S.P. Kauhanen, G. Komar, and M.P. Seppänen A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer Ann Surg 250 6 2009 957 963
22. V. Casneuf, L. Delrue, and A. Kelles Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions? Acta Gastroenterol Belg 70 4 2007 331 338
23. T.Y. Lee, M.H. Kim, and H. Park do Utility of 18F-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer AJR Am J Roentgenol 193 2 2009 343 348
24. Y. Nakamoto, T. Higashi, and H. Sakahara Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas Cancer 89 12 2000 2547 2554
25. M.W. Saif, D. Cornfeld, and H. Modarresifar 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients J Gastrointestin Liver Dis 17 2 2008 173 178
26. S. Heinrich, G.W. Goerres, and M. Schäfer Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness Ann Surg 242 2 2005 235 243
27. E. Topkan, C. Parlak, and A.F. Yapar FDG-PET/CT-based restaging may alter initial management decisions and clinical outcomes in patients with locally advanced pancreatic carcinoma planned to undergo chemoradiotherapy Cancer Imaging 13 3 2013 423 428
28. A. Asagi, K. Ohta, and J. Nasu Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence Pancreas 42 1 2013 11 19
29. H.X. Xu, T. Chen, and W.Q. Wang Metabolic tumour burden assessed by (1)(8)F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection Eur J Nucl Med Mol Imaging 41 6 2014 1093 1102
30. J.W. Lee, C.M. Kang, and H.J. Choi Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with pancreatic cancer J Nucl Med 55 6 2014 898 904
31. D. Schellenberg, A. Quon, and A.Y. Minn 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy Int J Radiat Oncol Biol Phys 77 5 2010 1420 1425
32. S.Y. Moon, K.R. Joo, and Y.R. So Predictive value of maximum standardized uptake value (SUVmax) on 18F-FDG PET/CT in patients with locally advanced or metastatic pancreatic cancer Clin Nucl Med 38 10 2013 778 783
33. J.Y. Kim, M.H. Kim, and T.Y. Lee Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging Am J Gastroenterol 103 5 2008 1145 1151
34. T.G. Park, F. Schmidt, and K. Caca Implication of lymph node metastasis detected on 18F-FDG PET/CT for surgical planning in patients with peripheral intrahepatic cholangiocarcinoma Clin Nucl Med 39 1 2014 1 7
35. R. Kluge, F. Schmidt, and K. Caca Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer Hepatology 33 5 2001 1029 1035
36. S. Seo, E. Hatano, and T. Higashi Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma Surgery 143 6 2008 769 777
37. U. Leung, N. Pandit-Taskar, and C.U. Corvera Impact of pre-operative positron emission tomography in gallbladder cancer HPB (Oxford) 16 2014 1023 1030
38. J.M. Butte, F. Redondo, and E. Waugh The role of PET-CT in patients with incidental gallbladder cancer HPB (Oxford) 11 7 2009 585 591
39. C. Ramos-Font, M. Gómez-Rio, and A. Rodríguez-Fernández Ability of FDG-PET/CT in the detection of gallbladder cancer J Surg Oncol 109 3 2014 218 224
40. H. Petrowsky, P. Wildbrett, and D.B. Husarik Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma J Hepatol 45 1 2006 43 50
41. J. Yoo, J.Y. Choi, and K.T. Lee Prognostic significance of volume-based metabolic parameters by (18)F-FDG PET/CT in gallbladder carcinoma Nucl Med Mol Imaging 46 3 2012 201 206
42. J.H. Donohue Present status of the diagnosis and treatment of gallbladder carcinoma J Hepatobiliary Pancreat Surg 8 6 2001 530 534
43. J.P. Hwang, I. Lim, and I.I. Na Prognostic value of suvmax measured by fluorine-18 fluorodeoxyglucose positron emission tomography with computed tomography in patients with gallbladder cancer Nucl Med Mol Imaging 48 2 2014 114 120
44. F. Redondo, J. Butte, and H. Lavados 18F-FDG PET/CT performance and prognostic value in patients with incidental gallbladder carcinoma J Nucl Med 53 515 2012 515
45. K. Okuda, T. Ohtsuki, and H. Obata Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients Cancer 56 4 1985 918 928
46. J.M. Llovet, J. Fuster, and J. Bruix The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma Liver Transpl 10 2 Suppl 1 2004 S115 S120
47. L.J. Wudel Jr., D. Delbeke, and D. Morris The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma Am Surg 69 2 2003 117 124 [discussion: 124-6]
48. K.T. Yoon, J.K. Kim, and Y. Kim do Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma Oncology 72 2007 104 110
49. J.E. Lee, J.Y. Jang, and S.W. Jeong Diagnostic value for extrahepatic metastases of hepatocellular carcinoma in positron emission tomography/computed tomography scan World J Gastroenterol 18 23 2012 2979 2987
50. T. Kawaoka, H. Aikata, and S. Takaki FDG positron emission tomography/computed tomography for the detection of extrahepatic metastases from hepatocellular carcinoma Hepatol Res 39 2 2009 134 142
51. C.Y. Lin, J.H. Chen, and J.A. Liang 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis Eur J Radiol 81 9 2012 2417 2422
52. J. Sims, M. Tann, and M. Baskin FDG PET/CT predicts overall survival in patiens with hepatocellular carcinoma J Nucl Med 54 Supplement 2 2014 1478
53. F. Xia, L. Wu, and W.Y. Lau Positive lymph node metastasis has a marked impact on the long-term survival of patients with hepatocellular carcinoma with extrahepatic metastasis PLoS One 9 2014 e95889
54. J. Park, I. Lim, and E. Cho Preoperative 18F-FDG PET/CT predicts the overall survival of patients with resectable hepatocellular carcinoma J Nucl Med 54 Supplement 2 2013 574
55. V. Pant, I.B. Sen, and A.S. Soin Role of (1)(8)F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma Nucl Med Commun 34 8 2013 749 757
56. A. Sabet, H. Ahmadzadehfar, and J. Bruhman Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET Nuklearmedizin 53 2 2014 39 45
57. O.N. Kucuk, C. Soydal, and M. Araz Prognostic importance of 18F-FDG uptake pattern of hepatocellular cancer patients who received SIRT Clin Nucl Med 38 2013 e283 e289
58. W.Y. Huang, C.H. Kao, and W.S. Huang 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy J Nucl Med 54 10 2013 1710 1716
59. R.A. Abbadi, U. Sadat, and A. Jah Improved long-term survival after resection of colorectal liver metastases following staging with FDG positron emission tomography J Surg Oncol 110 3 2014 313 319